Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Veloxis Pharmaceuticals A/S    VELO   DK0060048148

VELOXIS PHARMACEUTICALS A/S

(VELO)
  Report
 SummaryQuotesNewsRatingsCompanyFinancials 
Financials (USD)
Sales 2017 30,2 M - -
Net income 2017 -9,54 M - -
Net Debt 2017 18,1 M - -
P/E ratio 2017 -154x
Yield 2017 -
Sales 2018 39,5 M - -
Net income 2018 -5,29 M - -
Net Debt 2018 29,4 M - -
P/E ratio 2018 -708x
Yield 2018 -
Capitalization 1 601 M 1 644 M -
EV / Sales 2017 8,47x
EV / Sales 2018 15,3x
Nbr of Employees 60
Free-Float 10,00%
More Financials
Company
Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based commercial-stage specialty pharmaceutical company. The Company operates in the United States (US) through its subsidiary, Veloxis Pharmaceuticals Inc, based in Cary, North Carolina, US. The Company’s products include: Envarsus XR (tacrolimus extended-release tablets), a prescription medicine used with other medicines to help prevent... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about VELOXIS PHARMACEUTICALS A/S
02/17VELOXIS PHARMACEUTICALS A/S : Extraordinary General Meeting of Veloxis Pharmaceu..
AQ
01/29VELOXIS PHARMACEUTICALS A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmac..
AQ
01/27VELOXIS PHARMACEUTICALS A/S : - Notice to Convene Extraordinary General Meeting
AQ
01/27VELOXIS PHARMACEUTICALS A/S : Notice on Compulsory Acquisition to the Shareholde..
AQ
01/27VELOXIS PHARMACEUTICALS A/S : - Major Shareholder Notifications
AQ
01/24VELOXIS PHARMACEUTICALS A/S : Notice to Convene Extraordinary General Meeting
AQ
01/24VELOXIS PHARMACEUTICALS A/S : Announcement of Request for Delisting of Veloxis P..
AQ
01/24VELOXIS PHARMACEUTICALS A/S : Notice on Compulsory Acquisition to the Shareholde..
AQ
01/24VELOXIS PHARMACEUTICALS A/S : Major Shareholder Notifications
AQ
01/23VELOXIS PHARMACEUTICALS A/S : Increases Share Capital in Connection with Asahi K..
AQ
01/20VELOXIS PHARMACEUTICALS A/S : Asahi Kasei Pharma Denmark A/S Announces the Final..
AQ
01/17VELOXIS PHARMACEUTICALS A/S : Asahi Kasei Pharma Denmark A/S Announces the Final..
AQ
01/16VELOXIS PHARMACEUTICALS A/S : - Reporting of Managers and Closely Associated Per..
AQ
01/16VELOXIS PHARMACEUTICALS A/S : - Major Shareholder Notifications
AQ
01/16VELOXIS PHARMACEUTICALS A/S : - Asahi Kasei Pharma Denmark Announces the Prelimi..
AQ
More news
News in other languages on VELOXIS PHARMACEUTICALS A/S
2019BIOTECH TIME : scénario noir pour ASIT Biotech, GeNeuro lance une nouvelle phase..
2018VELOXIS PHARMACEUTICALS A/S : publication des résultats trimestriels
2018VELOXIS PHARMACEUTICALS A/S : Veröffentlichung des Quartalsergebnisses
2018VELOXIS PHARMACEUTICALS A/S : publication des résultats semestriels
2018VELOXIS PHARMACEUTICALS A/S : Veröffentlichung des Halbjahresergebnisses
More news
Chart VELOXIS PHARMACEUTICALS A/S
Duration : Period :
Veloxis Pharmaceuticals A/S Technical Analysis Chart | VELO | DK0060048148 | MarketScreener
Income Statement Evolution
Managers
NameTitle
Craig A. Collard President & Chief Executive Officer
Stacy Wheeler Vice President-Operations
Ira Duarte Chief Financial Officer & VP-Controller
Ulf Meier-Kriesche Chief Scientific Officer
Masaya Etoh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VELOXIS PHARMACEUTICALS A/S-0.50%1 644
MERCK KGAA23.40%67 032
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD98.85%20 190
KYOWA KIRIN CO., LTD.6.80%14 219
BETTA PHARMACEUTICALS CO., LTD.51.90%6 685
YUHAN CORPORATION39.75%3 707